About the Journal | Editorial Board | Instructions to Contributors | Submission & Review | Advertise with Us | Subscribe to E- Alerts
Sitemap | Feedback
Advanced search
Journal of Case Reports
Nab-Paclitaxel in Patients with Advanced Pancreatic Cancer: Case Series
J B Sharma1, Palanki Satya Dattatreya2
1Consultant Medical Oncologist at Rajiv Gandhi Cancer Institute and Research Center, New Delhi; 2Senior Consultant Medical Oncologist, Hyderabad, Andhra Pradesh, India.
Corresponding Author:
Dr. Jai Bhagwan Sharma
Email: silversword44@yahoo.com
Received: 23-JUN-2014 Accepted: 16-JUL-2014 Published Online: 10-AUG-2014
DOI: http://dx.doi.org/10.17659/01.2014.0074
Introduction: Pancreatic cancer is one of the top ten causes of cancer related deaths world-wide. The only treatment offering an advantage in terms of overall survival is radical complete resection of pancreatic carcinoma. But, only 10-20% present with resectable disease at the time of diagnosis. Single agent gemcitabine still remains the standard therapy for advanced/ metastatic pancreatic cancer after indecisive conclusions with combination therapy of oxiplatin and gemicitabine. Nab-paclitaxel (albumin bound paclitaxel) has demonstrated a better overall survival in phase III trials in combination with gemcitabine. Case Report: The two cases mentioned below are cases of advanced pancreatic cancer which have demonstrated an affirmative response to combination therapy of nab-paclitaxel and gemcitabine in first line and beyond. Conclusion: Gemcitabine, although the standard of care in the treatment of advanced pancreatic cancer, shows better efficacy and survival when used in combination with nab-paclitaxel.
Keywords : Paclitaxel, Deoxycytidine, Pancreatic Neoplasms, Oxiplatin, Humans.
Article Options
Search PubMed for
Search Google Scholar for
Article Statistics
Bookmark and Share